Growth differentiation factor 15 in cardiovascular diseases: From bench to bedside

Biomarkers

Volumn 16, Issue 6, 2011, Pages 466-475

  Xu, Xinye ^a   Li, Zijian ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

cardiovascular disease; GDF 15; myocardial protection

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 5F 203; ACETYLSALICYLIC ACID; ALLYL SULFIDE; CAPSAICIN; CELECOXIB; CONJUGATED LINOLEIC ACID; DICLOFENAC; DIINDOLYLMETHANE; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; GENISTEIN; GROWTH DIFFERENTIATION FACTOR 15; IBUPROFEN; INDOMETACIN; LYCOPENE; NETOGLITAZONE; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; SALICYLATE SODIUM; SC 5SI25; SULFORAPHANE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL SURVIVAL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NONHUMAN; PROGNOSIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ACUTE CORONARY SYNDROME; BIBLIOGRAPHY AS TOPIC; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; REPERFUSION INJURY; RISK FACTORS; SIGNAL TRANSDUCTION; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 80051962950     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.580006     Document Type: Review

References (71)

1. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG, Hegi ME. (2002). Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 21:4212-4219. (Pubitemid 34753827)
2. Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F. (2009). PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 30:824-831.
3. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman R, Maxwell PH, Choi P. (2010). Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95:505-508.
4. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. (2004). Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 279:6883-6892. (Pubitemid 38248831)
5. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. (2005). Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67:356-364. (Pubitemid 40216727)
6. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN. (2005). The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 65:2330-2336. (Pubitemid 40490143)
7. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, Breit SN. (2006). Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66:4983-4986. (Pubitemid 43852864)
8. Bjørnstad JL, Neverdal NO, Vengen OA, Knudsen CW, Husebye T, Pepper J, Lie M, Christensen G, Tønnessen T. (2008). Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodeling in patients operated for severe aortic stenosis. Eur J Heart Fail 10:1201-1207.
9. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. (2011). Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 31:203-210.
10. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514-11519. (Pubitemid 27451030)
11. Böttner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter- Crazzolara C. (1999). Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 237:105-111.
12. Cekanova M, Lee SH, Donnell RL, Sukhthankar M, Eling TE, Fischer SM, Baek SJ. (2009). Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev Res (Phila) 2:450-458.
13. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J. (2004). Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64:5929-5933. (Pubitemid 39129386)
14. Chen YL, Lin PC, Chen SP, Lin CC, Tsai NM, Cheng YL, Chang WL, Lin SZ, Harn HJ. (2007). Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase mitogen-activated protein kinase revealed a isochaihulactonetriggered apoptotic pathway in human lung cancer A549 cells. J Pharmacol Exp Ther 323:746-756.
15. de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A, de Waard V, Heijnen CJ, Muriana FJ, Weber C, van Berkel TJ,Kuiper J, Lee SJ, Abia R, Biessen EA. (2011). Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2- mediated macrophage chemotaxis. J Exp Med. Available from: .
16. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C. (2009). Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 150:1688-1696.
17. Dostálová I, Roubícek T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D, Kaválková P, Matoulek M, Kasalicky M, Haluzík M. (2009). Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 161:397-404.
18. Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert KC. (2008). Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 29:2327-2335.
19. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, Wollert KC, Wallentin L. (2010). Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 3:88-96.
20. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A. (2005). The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide. Clin Cancer Res 11:4610-4619. (Pubitemid 40825652)
21. Foley PW, Stegemann B, Ng K, Ramachandran S, Proudler A, Frenneaux MP, Ng LL, Leyva F. (2009). Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J 30:2749-2757.
22. Heger J, Schiegnitz E, von Waldthausen D, Anwar MM, Piper HM, Euler G. (2010). Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 224:120-126.
23. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. (2007). Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 13:5825-5833. (Pubitemid 47583907)
24. Huh SJ, Chung CY, Sharma A, Robertson GP. (2010). Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol 176:2948-2957.
25. Jang TJ, Kang HJ, Kim JR, Yang CH. (2004). Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis 25:1853-1858. (Pubitemid 39405904)
26. Kadara H, Schroeder CP, Lotan D, Pisano C, Lotan R. (2006). Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther 5:518-522. (Pubitemid 43765287)
27. Karan D, Holzbeierlein J, Thrasher JB. (2009). Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res 69:2-5.
28. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. (2006). The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351-360.
29. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. (2007a). Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-1060. (Pubitemid 47348231)
30. Kempf T, Björklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. (2007b). Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 28:2858-2865. (Pubitemid 350233034)
31. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. (2007c). Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53:284-291. (Pubitemid 46338273)
32. Kempf T, Sinning JM, Quint A, Bickel C, Sinning C, Wild PS, Schnabel R, Lubos E, Rupprecht HJ, Münzel T, Drexler H, Blankenberg S, Wollert KC. (2009a). Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet 2:286-292.
33. Kempf T, Wollert KC. (2009b). Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34:594-599.
34. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. (2009). Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 30:1057-1065.
35. Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE. (2002). Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 122:1388-1398. (Pubitemid 34465181)
36. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. (2008a). Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704-712. (Pubitemid 351494157)
37. Kim JH, Kim KY, Jeon JH, Lee SH, Hwang JE, Lee JH, Kim KK, Lim JS, Kim KI, Moon EY, Lee HG, Ryu JH, Yang Y. (2008b). Adipocyte culture medium stimulates production of macrophage inhibitory cytokine 1 in MDA-MB-231 cells. Cancer Lett 261:253-262.
38. Kim JH, Chang JH, Rhee KH, Yoon JH, Kwon SH, Song K, Lee KW, Cho CI, Jeon JH, Kim KS. (2008c). Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Int J Cancer 122:1765-1773. (Pubitemid 351413422)
39. Kim MY, Moon JY, Hwang JW, Lee SY, Joo YM, Han SI, Park HG, Kang HS. (2008d). Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/ MEK1/2 inhibitors in A549 human lung adenocarcinoma cells. Biochem Pharmacol 75:1751-1760.
40. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC. (2008). Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 177:1018-1025. (Pubitemid 351717597)
41. Lee SH, Yamaguchi K, Kim JS, Eling TE, Safe S, Park Y, Baek SJ. (2006). Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27:972-981.
42. Lee SH, Krisanapun C, Baek SJ. (2010). NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 31:719-728.
43. Lim JH, Park JW, Min DS, Chang JS, Lee YH, Park YB, Choi KS, Kwon TK. (2007). NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in HCT116 colon carcinoma cells. Apoptosis 12:411-421. (Pubitemid 46169920)
44. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. (2009). Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Eur Heart J 30:2346-2353.
45. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN, Panhurst S. (2003). Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034-5040. (Pubitemid 37022642)
46. Meadows CA, Risbano MG, Zhang L, Geraci MW, Tuder RM, Collier DH, Bull TM. (2010). Increased expression of growth differentiation factor-15 in scleroderma-associated pulmonary arterial hypertension. Chest. Available from: . chestpubs.org/content/early/2010/09/07/chest.10-0302.long.
47. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. (2008). Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:534-541.
48. Pang RP, Zhou JG, Zeng ZR, Li XY, Chen W, Chen MH, Hu PJ. (2007). Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett 251:268-277. (Pubitemid 46671612)
49. Park JY, Park KH, Bang S, Kim MH, Koh SS, Song SY. (2008). Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas. J Cancer Res Clin Oncol 134:1029-1035.
50. Park YJ, Lee H, Lee JH. (2010). Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. bmb Rep 43:91-96.
51. Piyanuch R, Sukhthankar M, Wandee G, Baek SJ. (2007). Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 258:230-240. (Pubitemid 350110378)
52. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, Metz J, Kinscherf R. (2004). Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 318:325-333. (Pubitemid 39506502)
53. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK. (2010). Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 29:1293-1302.
54. Shim M, Eling TE. (2005). Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 280:18636-18642. (Pubitemid 41379563)
55. Shim M, Eling TE. (2008). Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism. Mol Cancer Ther 7:961-971. (Pubitemid 351551050)
56. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. (2010). The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12:1309-1316.
57. Stejskal D, Karpísek M, Humenanská V, Lacnák B, Svesták M. (2009). Macrophage-inhibitory cytokine-1 (mic-1) in differential diagnosis of dyspnea-a pilot study. Clin Biochem 42:1347-1351.
58. Strelau J, Strzelczyk A, Rusu P, Bendner G, Wiese S, Diella F, Altick AL, von Bartheld CS, Klein R, Sendtner M, Unsicker K. (2009). Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 29:13640-13648.
59. Subramaniam S, Strelau J, Unsicker K. (2003). Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem 278:8904-8912. (Pubitemid 36800366)
60. Sun T, Huang Y, Phillips MI, Luo X, Zhu J, Shi H, Li J. (2010). Growth differentiation factor 15 and coronary collateral formation. Clin Cardiol 33:E1-E5.
61. Ago T, Sadoshima J. (2006). GDF15, a cardioprotective TGF- superfamily protein. Circ Res 98:294-297.
62. Wang F, Guo Y, Yu H, Zheng L, Mi L, Gao W. (2010). Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 15:671-676.
63. Wang X, Yang X, Sun K, Chen J, Song X, Wang H, Liu Z, Wang C, Zhang C, Hui R. (2010). The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci 118:137-145.
64. Wang Y, Yu H, Xu M, Gao W. (2010). Expression and significance of growth differentiation factor-15 in myocardial fibroblast. Chin J Med Guide 12:633-635.
65. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. (2007a). Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115:962-971. (Pubitemid 46328289)
66. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L. (2007b). Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 116:1540-1548. (Pubitemid 47511417)
67. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-350.
68. Yamaguchi K, Lee SH, Eling TE, Baek SJ. (2004). Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/ GSK-3beta pathway. j Biol Chem 279:49617-49623. (Pubitemid 39577764)
69. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. (2003). Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2:1023-1029.
70. Yang H, Choi HJ, Park SH, Kim JS, Moon Y. (2009). Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem Pharmacol 78:1205-1213.
71. Zimmers TA, Gutierrez JC, Koniaris LG. (2010). Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol 136:571-576.